Objective-Tremendous efforts have been made to establish effective therapeutic neovascularization using adipose tissue-derived stromal vascular fraction (SVF), but the efficiency is low, and underlying mechanisms and their interaction with the host in a new microenvironment are poorly understood. Methods and Results-Here we demonstrate that direct implantation of SVF derived from donor adipose tissue can create a profound vascular network through the disassembly and reassembly of blood endothelial cells at the site of implantation. This neovasculature successfully established connection with recipient blood vessels to form a functionally perfused circuit. Addition of vascular growth factors to the SVF implant improved the efficiency of functional neovasculature formation. In contrast, spheroid culture of SVF before implantation reduced the capacity of vasculature formation, possibly because of cellular alteration. Implanting SVF into the mouse ischemic hindlimb induced the robust formation of a local neovascular network and salvaged the limb. Moreover, the coimplantation of SVF prevented fat absorption in the subcutaneous adipose tissue graft model. Conclusion-Freshly isolated SVF can effectively induce new vessel formation through the dynamic reassembly of blood endothelial cells and could be applied to achieve therapeutic neovascularization for relieving ischemia and preventing fat absorption in an autologous manner. 
S
VF is a mixture of blood endothelial cells (BECs), adipocyte progenitors, immune cells, fibroblasts, pericytes, and stromal cells, as well as yet undefined stem/ progenitor cells. [1] [2] [3] [4] Previous studies have shown that mesenchymal stem/progenitor cells in stromal vascular fraction (SVF) can be cultured to successfully differentiate into adipocytes, pericytes, osteoblasts, chondrocytes, and myocytes under optimized conditions. 1, 2, 5, 6 These observations of in vitro culture prompted the application of cells isolated from SVF in fields of regenerative medicine, such as the use of adipose-derived stem/progenitor cells (ADSCs) or adipose-derived regenerative cells, which are known to be multipotent mesenchymal stem cells. 7, 8 In most cases, the main strategy is to isolate ADSCs from small quantities of subcutaneous adipose tissue (SAT) retrieved by minimally invasive surgery, further expand them in vitro, and implant the cells into damaged tissues. 7, 8 However, several drawbacks of such cell therapy do exist. First, the intrinsic stemness of freshly isolated SVF is rarely maintained during culture. Second, the outcome of implanted ADSCs has not been measurable in terms of cell survival and function. Third, the in vitro ADSC differentiation is not readily reproducible in the in vivo microenvironment, and therefore, after implantation, ADSCs would often fail to establish the intended cell population. Moreover, our understanding in the nature of ADSCs and their ultimate fate after implantation remains far from satisfactory, raising safety concerns.
Reasonable means to achieve neovascularization that would ensure circulation should be pursued to relieve chronic complications and minimize the acute/subacute staged ischemic penumbra of occlusive vascular disorders. Tremendous efforts have been made to establish protocols using angiogenic cytokines, adult stem cells, umbilical vein endothelial cells, and endothelial progenitor cells (EPCs) supplemented with the extracellular matrixes to attain effective therapeutic neovascularization. 9 -13 Several attempts 14 -18 have been made to attain therapeutic neovascularization, adopting either BECs derived from adipose tissue or ADSCs. Early studies showed that freshly enriched BECs from adipose tissue could be beneficial for therapeutic reendothelialization. 19, 20 Interestingly, implantation of freshly isolated microvessel fragments from adipose tissue underwent angiogenic sprouting and interfaced with the recipient vessels within a day. 14 Some researchers have claimed that CD34 ϩ /CD31 Ϫ cells derived from cultured human ADSCs are capable of differentiating into BECs, and subsequent augmentation of blood flow through increased vasculature of ischemic hindlimbs takes place. 15, 16 However, whether ADSCs are actually capable of differentiating into BECs remain controversial. 17, 18 Recently, Traktuev et al demonstrated that the majority of CD34 ϩ cells of freshly isolated SVF are actually resident pericytes, which associate with BECs and stabilize the vascular network. 21 Moreover, they extended their study and showed that implants adopting the combination of EPCs and ADSCs yield a much higher neovascularization capacity than when either EPCs or ADSCs were implanted alone and that the implanted EPCs and ADSCs contribute to form the vascular mural layer. 22 This reciprocal interaction between ADSCs and EPCs indicates that if they are appropriately combined, neovascularization can be induced in a synergistic manner.
Nowadays, millions of people receive autologous fat tissue augmentation for cosmetic and reconstructive purposes, 23, 24 but one of the major concerns for this procedure is the shrinkage of adipose tissue over time, mainly due to the loss of adipocytes (fat absorption) and replacement of dead space with fibrotic tissue. [25] [26] [27] Although the primary cause for fat absorption is believed to be insufficient blood supply or supporting matrix to nurture and maintain the implanted adipose tissues, the actual mechanism of this process is poorly understood.
In this study, we determined the cellular events occurring in the process of SVF-derived vascular network formation and explored the possibilities of freshly isolated SVF as a source candidate for cell therapy. Here, we suggest their potential therapeutic applications. We showed that freshly isolated donor SVF can readily provide BECs to create a vascular network through a disassembly and reassembly mechanism, which can establish functional communication with the circulation of the recipient. We investigated the clinical implications of this phenomena and demonstrated that SVF delivery can be applied to rescue a mouse hindlimb ischemia or prevent fat absorption in SAT implants.
Methods

Animals
Specific pathogen-free C57BL/6J mice (B6), Tie2-green fluorescent protein (GFP) ϩ mice (C57BL/6J genetic background), discosoma sp. Red (dsRed) ϩ mice (C57BL/6J genetic background), and BALB/ cByJ athymic nude mice (CbyJ.Cg-Foxn1 nu /J) were purchased from the Jackson Laboratory. GFP ϩ mice (B6 genetic background) were a gift from Dr Masaru Okabe (Osaka University, Japan).
Isolation of SVF From Adipose Tissue
Because epididymal adipose tissue (EAT) has no adjacent tissues, we isolated the SVF from the EAT of B6, dsRed ϩ , GFP ϩ , and Tie2-GFP ϩ mice to avoid contamination from nonadipose tissues as previously described. 4 
Implantation of SVF
A total of 3ϫ10 5 SVF cells were mixed with Matrigel (100 L, growth factor reduced, BD Biosciences) or collagen type I gel (100 L, BD Biosciences) containing phosphate-buffered saline (PBS), bovine serum albumin (BSA) (100 ng), vascular endothelial growth factor (VEGF) (50 ng), or cartilage oligomeric matrix proteinangiopoietin 1 (Ang 1) (100 ng) 28 and implanted into the flank region subcutaneously of 8-week-old B6, GFP ϩ , or FVB/NJ mice. Supplemental Methods are available online at http://atvb.ahajournals.org.
Results
Direct Implantation of SVF With Matrigel Forms a Profound Vascular Network
First, we were curious what kind of structure would be formed if we implanted SVF directly into a subcutaneous compartment. To avoid contamination from nonadipose tissues, we isolated the SVF from EAT, which is free from other tissues as we previously described. 4 To distinguish implanted donor SVF from that of recipients, we harvested SVF from GFP ϩ , dsRed ϩ , or Tie2-GFP ϩ mice and implanted them into their syngeneic normal or GFP ϩ mice. Two weeks after implantation, the implanted SVF formed a group of disorganized cells ( Figure 1A ). In contrast, SVF implanted as a mixture with Matrigel (growth factor reduced) formed a network suggestive of vascular architecture ( Figure 1A ). To identify this network, we harvested SVF from dsRed ϩ mice, mixed them with Matrigel, and implanted the mixture into GFP ϩ mice ( Figure 1B ). The entire platelet endothelial cell adhesion molecule-1 ϩ (PECAM-1 ϩ ) vascular structures were shown to be derived from the donor dsRed ϩ SVF, without identifiable contribution from the GFP ϩ recipient ( Figure  1B ). In parallel, we isolated the SVF from SAT of GFP ϩ mice, mixed them with Matrigel, and implanted the mixture into syngeneic normal mice (Supplemental Figure IA and IB) . Formation of the SVF-derived vascular network between the SAT and EAT was almost identical (Supplemental Figure IA and IB). In addition, to distinguish the effect of supporting matrix from growth factors in the SVF-derived vascular network formation, we mixed SVF from GFP ϩ mice with Matrigel or collagen type I gel and compared the effects at 2 weeks after implantation. Activities of the SVF-derived vascular network formation between the Matrigel and collagen type I gel were almost identical (Supplemental Figure IC and ID). These data indicate that direct implantation of SVF gives rise to vascular structures in a syngeneic recipient but requires a supporting matrix. We observed the SVF-derived vascular network to persist in the recipient throughout the entire experimental period of up to 6 months (Supplemental Figure IE) . The other donor cells in the Matrigel that failed to participate in the established vascular network gradually disappeared over time, and corresponding fluorescent signal was detected mainly in the spleen (data not shown), presumably reflecting a degradation process.
The process of SVF-derived vascular formation seems to be substantially influenced by alterations of populations and cellular senescence. Freshly isolated SVF derived from EAT successfully managed to form a de novo vascular network. However, the implants of spheroids produced by hanging drop culture of SVF after 2 passages often, but not always, produced vascular networks in the matrix (Supplemental Figure IIA and IIB). In contrast, implants of single-cell suspension of SVF or cultured SVF spheroids after 6 passages failed to form a vascular network in the matrix (data not shown and Supplemental Figure IIA and IIB). In fact, our flow cytometric analyses revealed that populations of CD31 ϩ endothelial cells and CD45 ϩ myeloid cells were largely decreased, whereas CD31 Ϫ / CD45 Ϫ /Ter119 Ϫ mesenchymal cells, including fibroblasts, were mostly populated during serial culture of SVF (Supplemental Figure IIC ). In addition, we observed that the number of senescence-associated ␤-galactosidase ϩ cells was increased during serial culture of SVF (Supplemental Figure IID) . These observations led us to investigate how SVF implants form new vascular structures, how they interact with the recipient, and how we could take advantage of them for therapeutic purposes.
SVF Forms Connecting Blood Vessel Networks Sparsely With Recipient Blood Vessels
The Tie2-GFP ϩ mouse is an useful model with which to label BECs and a subset of hematopoietic cells. 29 To trace the fate of SVF-derived BECs in the process of vascular network formation, we implanted SVF of Tie2-GFP ϩ mice into syngeneic normal mice ( Figure 1C ). A vascular network consisting of Tie2-GFP ϩ /PECAM-1 ϩ blood vessels was observed 2 weeks after implantation, indicating the foundation of the structure to be the implanted Tie2-GFP ϩ SVF ( Figure 1C ). Therefore, we interpret BECs to be the main cellular components responsible for SVFderived vascular network formation. Higher magnification of the peripheral regions of the implanted Matrigel revealed sparse connections between the organized SVFderived vasculatures and GFP Ϫ /PECAM-1 ϩ recipient vasculatures, indicating the low efficiency of the newly formed vessels in establishing connections with the recipient vessels ( Figure 1C ).
SVF-Derived Vasculatures Require Vascular Growth Factors to Achieve Functional Circulation
The above findings led us to perform a perfusion assay to determine whether the SVF-derived vascular network was functional. SVF from dsRed ϩ mice in Matrigel was implanted and maintained for 2 weeks. Then fluorescein isothiocyanate (FITC)-lectin was injected into the tail vein 15 minutes before the SVF containing region was sampled ( Figure 1D ). Both the donor (dsRed ϩ /PECAM-1 ϩ ) and recipient (dsRed Ϫ /PECAM-1 ϩ ) origin vessels were detected, but FITC-lectin was not readily detectable in the donorcontributed vasculatures ( Figure 1E ). In contrast, FITC-lectin was well perfused in the recipient-originated dsRed Ϫ / PECAM-1 ϩ vessels ( Figure 1E ). To test whether adding vascular growth factors would improve the perfusion of SVF-derived vasculatures, 2 major vascular growth factors-VEGF-A and Ang1-were added into Matrigel before implantation. Compared with the control, vascular perfusion in vessels formed by SVF was promoted 4.3-fold by the supplementation of VEGF-A (50 ng), 3.6-fold by supplementation of Ang1 (100 ng), and 9.7-fold by supplementation of VEGF-A (50 ng) plus Ang1 (100 ng) ( Figure 1E and 1G ). In addition, supplementation of these vascular growth factors slightly but not significantly increased the vascular density ( Figure 1F ). In fact, the effect of supplemented growth factors, in terms of proliferative activity, on SVF-derived vasculatures and surrounding recipient vasculatures was limited or even negligible. However, the sprouting activity of SVF-derived vasculatures was promoted by growth factor supplementation (Supplemental Figure III) . Conversely, we inhibited the action of VEGF-A and angiopoietins by adding copious amounts of VEGF-A blocker (VEGF-Trap) and angiopoietin blocker (sTie2-Fc). Compared with the control mice treated with Fc, the SVF-derived vascular density decreased by 27.6% by treating with VEGF-Trap, 48.9% by treating with sTie2-Fc, and 72.4% by treating with both VEGF-Trap and sTie2-Fc (Supplemental Figure IV) . Collectively, vascular growth factors are essential for SVF-derived vasculatures to achieve functional perfusion and maintain vessel density.
Vascular Networks Formed By SVF Require Macrophages for Proper Structural Organization
SVF also contains macrophages, which secrete a battery of vascular growth factors and cytokines. 30 To investigate the role of macrophages in SVF-derived vascular network formation, we depleted macrophages (Ͼ95%, measured by flow cytometric analysis for CD11b ϩ and F4/80 ϩ cells and immunohistochemistry for F4/80, Supplemental Figure VA and VB) in the donor and recipient by treating clodronate liposome (CDL) 31 to the mice before harvesting or implanting SVF ( Figure 2A) . As a control, control liposome (CL) was treated to donor mice. Consequently, macrophage-depleted SVF or control SVF were implanted into either the recipient macrophage-depleted mice or control mice, respectively (Figure 2A) . Marked reduction of vascular networks in the central and peripheral regions of the implants was observed in the macrophage-depleted mice bearing the macrophage-depleted donor SVF (group 4, Figure 2 ). Interestingly, these mice frequently exhibited large but blunt-ended GFP ϩ /PECAM-1 ϩ disconnected vessels in the central region of the implant ( Figure 2C ). Although the macrophage-depleted mice that received control SVF (group 2) displayed relatively abundant vasculature in the central region of the implant, still a marked reduction of vascular networks in the peripheral region was detected ( Figure 2 ). In comparison, the control mice that received the macrophage-depleted donor SVF (group 3) displayed relatively abundant vasculature (Figure 2 ). These observations indicate that the recipient macrophages actively participate in the process of establishing a vascular network between the implanted donor SVF and recipient mice vasculature. Furthermore, these abnormalities of vascular network of implanted donor SVF by macrophage depletion were partially (77.2% and 59.8% in the central and peripheral regions, respectively) recovered by supplementation of VEGF-A (50 ng) (Supplemental Figure VC and VD) , indicating that VEGF-A and other angiogenic growth factors secreted from the macrophage contribute to forming the vascular network.
SVF Forms Hybrid Vascular Networks Through Dynamic Reassembly of BEC Network in the Adipose Tissue
We questioned how SVF forms an organized vascular network in such a quick and efficient manner. We hypothesized that the vascular network formed by SVF in the Matrigel could be built simply by rearranging the preexisting blood vessel components, because adipose tissues possess relatively abundant blood vasculatures (Supplemental Figure VIA) . Consistent with previous finding, 32 our flow cytometric analyses revealed that approximately 7% of SVF consist of BECs (Supplemental Figure VIB) . To validate our hypothesis, we isolated the
Ϫ , and CD31 Ϫ /CD45 Ϫ /Ter119 ϩ , from SVF using fluorescence-activated cell sorting, and each was plated onto a Matrigel-coated plate to examine vascular network formation in vitro. However, isolated CD31
ϩ failed to achieve vascular network formation in vitro, whereas isolated CD31 ϩ /CD45 Ϫ /Ter119 Ϫ cells were able to form a vascular network in vitro (Supplemental Figure VID) . Moreover, the CD31 ϩ /CD45 Ϫ /Ter119 Ϫ BECs or non-BECs, including the combination of CD31
Ϫ /CD45 ϩ /Ter119 Ϫ , and CD31 Ϫ /CD45 Ϫ /Ter119 ϩ , from SVF were mixed with Matrigel that contained either vascular growth factors (50 ng of VEGF-A and 100 ng of Ang1) or BSA (100 ng), before implantation ( Figure 3A) . Only the BEC-enriched implants formed a vascular network, and the addition of vascular growth factors increased the vessel density by 1.34-fold compared with BSAsupplemented SVF (Figure 3 ). In comparison, the non-BECsenriched implants failed to form a vascular network in spite of the presence of vascular growth factor supplements ( Figure  3) . To trace the origin of the BEC components in the SVF, we harvested SVF from GFP ϩ mice and dsRed ϩ mice, mixed the cells together at a 1:1 ratio in Matrigel, and implanted the mixture into a normal B6 recipient ( Figure  4A ). Two weeks later, CD31 ϩ vascular networks were found that were composed of intermingled GFP ϩ BECs and dsRed ϩ BECs ( Figure 4B ), suggesting that the new vessels were built by rearranging the BECs contained in the donor SVF. Collectively, SVF-derived BECs establish a hybrid vascular network in the recipient through the disassembly and reassembly of the preexisting blood vessel components in the donor adipose tissue ( Figure 4C ).
SVF-Derived Vascular Networks Rescue Hindlimb Ischemia
To explore whether the SVF-derived vascular network formation can provide potential benefits to relieve ischemia, we implanted SVF directly into the muscles of an ischemic mouse hindlimb 33 (Supplemental Figure VIIA) . Implanted SVF effectively formed new vascular networks ( Figure 5 ). In the case of SVF implantation into the ischemic hindlimb, unlike normal B6 recipients, the presence or absence of Matrigel did not cast a significant difference in the blood vessel density (Figure 5A and 5B). These SVF-derived vessels frequently exhibited connections with the adjacent recipient blood vessels, which were found to be well perfused by FITC-lectin ( Figure 5C and Supplemental Figure VIIB) . Noticeably, SVF did not contribute to form pericytes in the ischemic tissue (Supplemental Figure VIIC) . Compared with the implantation of an equal number of 3T3 cells, the SVF implantation even without Matrigel induced a 5.8-fold increase of blood perfusion in the ischemic limb on day 7, achieving an 8.2-fold increase of hindlimb salvage ( Figure  5D to 5G). Moreover, the SVF implantation induced more pronounced proliferative activity, antiapoptosis, and antiinflammation in the injection areas for salvage of the ischemic limb compared with the implantation of 3T3 cells (Supplemental Figure VIID to VIIG).
SVF-Derived Blood Vessels Supplemented With Vascular Growth Factors Can Prevent Fat Absorption of the Coimplanted SAT
Fat absorption of the SAT implant is a major drawback for autologous fat tissue transplantation in the field of plastic surgery. 25, 34 We extended our study to see whether the SVF-derived vascular network could be applied to inhibit fat absorption of SAT implants. To address this matter, we attempted coimplantation of dsRed ϩ SAT with GFP ϩ SVF into syngeneic recipients (Supplemental Figure VIIIA) . The dsRed ϩ SAT implanted recipients were categorized into 4 study groups according to whether the coinjected Matrigel contained BSA only (group 1), vascular growth factors only (50 ng of VEGF-A and 100 ng of Ang1) (group 2), or GFP ϩ SVF either with or without vascular growth factor supplements (groups 3 and 4) ( Figure 6A , Supplemental Figure  VIIIA) . Overall, group 4 showed profound dsRed ϩ SATderived and GFP ϩ SVF-derived vascular networks in both the central and peripheral regions of SVF implant ( Figure 6B to  6E) . To clarify the presence or absence of adipocytes in the implants, we incubated the tissues with BODIPY, a specific marker for neutral lipid. The SAT implanted only with BSA (group 1) had almost no remaining adipocytes ( Figure 6B to 6E). In comparison, the adipocyte content increased by 17.8-fold when vascular growth factors were supplemented, 33.6-fold when SVF was coimplanted, and 40.8-fold when both vascular growth factors and SVF were coimplanted ( Figure 6B and 6E). Our confocal microscopic analysis revealed that all BODIPY ϩ cells in the central portion of implants were dsRed ϩ adipocytes derived from implanted SAT (data not shown). In group 4, hybrid vasculatures composed of BECs originating from both the GFP ϩ SVF and dsRed ϩ SAT were frequently observed at the implant periphery (Supplemental Figure VIIIB) . However, hybrid vessels were rarely detectable in the implant center ( Figure 6B ).
SVF Forms Abnormal Blood Vessel Structures and BEC Junctions in the Allograft
Allografting with BECs directly activates CD8 ϩ T cells and triggers immune rejection. 35 To investigate the degree of immune rejection, we harvested SVF from GFP ϩ mice (B6 background, H-2 b haplotype), mixed the cells with Matrigel, and implanted them into FVB/NJ mice (H-2 q haplotype) (Supplemental Figure IXA) . Two weeks later, we found abnormal vascular networks, which were characterized by disconnected and blunt-ended vessels (Supplemental Figure  IXB) . Moreover, disarrangements of PECAM-1, an endothelial cell junction marker, were detected at the blunt-ended vessels (Supplemental Figure IXC) .
Discussion
In this study, we show that direct implantation of freshly isolated SVF derived from adipose tissue can induce a rapid and robust process of vascular network formation through the dynamic reassembly of BECs at the site of implantation in syngeneic mice. This neovascular formation is quite different from the traditional concept in which new vessels are formed by either vasculogenesis or angiogenesis. 36, 37 Therefore, we addressed the following question: How could SVF form such a speedy and profound vascular network? We identify this phenomenon to occur mainly through a process of recycling the factorized preexisting cellular components in SVF instead of building them de novo, namely the disassemblyreassembly of BECs mechanism, which differs from either vasculogenesis or angiogenesis.
Adipose tissue is abundant in a fine, delicate, and wellorganized blood vessel network, of which BECs have been measured as making up Ϸ7% of the cellular components. 32 We found that most of the vasculatures in the adipose tissue are disassembled during the preparation procedures of SVF by collagenase digestion, resulting in a BEC suspension. Our data based on the implantation of CD31 ϩ /CD45 Ϫ /Ter119 BECs enriched from SVF and the implantation of an SVF mixture obtained from both GFP ϩ mice and dsRed ϩ mice provide compelling evidence that the BECs in freshly isolated SVF do form hybrid vascular networks. These observations support our hypothesis regarding the disassembly-reassembly of BECs. However, we assumed that angiogenesis would also be required for connecting the SVF-derived vessels with the recipient vessels. In fact, we found that the implanted SVF-derived BECs require appropriate supporting matrix (Matrigel), endogenous or supplemental vascular growth factors, and macrophages of the recipient to successfully complete the construction of a new vascular network. In particular, vascular growth factor supplements were critical to provoke the implanted SVF-derived BECs to complete a functional perfusion circuit with the recipient vessels. Moreover, consistent with a recent report, 38 the host myeloid cells including macrophages showed profound contribution in the process of establishing engineered vascular network. During this process, sprouting activity was quite active, whereas proliferative activity was infrequently detectable in the BECs of implanted SVF. Therefore, the sprouting process could be responsible for the connection and establishment of the SVF-derived vessels with the recipient vessels.
In addition, our results suggest that population alteration or cellular senescence has a substantial influence over the capacity of SVF in vessel formation. Spheroids formed with Ͼ5 passages of SVF failed to effectively create a vascular network. Previous studies using ADSCs 16, 17 describe limited vascular network formation, which could be due to the loss of BECs and senescence from excessive SVF culture passages. 39 Therefore, it would be advisable to use freshly isolated SVF instead of the products of in vitro culture. For therapeutic purposes, using freshly isolated SVF is also beneficial in terms of convenience and safety. However, it remains to be determined whether the non-BECs could induce adverse side effects, although we observed the non-BEC components of SVF to be deposited and presumably degraded in the spleen. In fact, the use of pure BECs from SVF could be considered to avoid possible side effects. However, the neovascular efficacy using pure BECs is less than that using the total SVF, and an additional step for purification is required, which is quite laborious and difficult. Moreover, we have not found any difference between the ability of SAT and EAT in vascular network formation. Recent reports 40, 41 indicate that cultured pericytes from human tissues, including adipose tissue and saphenous vein, can be exploited as a source of mesenchymal stem cells that exhibit myogenic capacity under in vitro and in vivo inductive conditions. In particular, the CD34 ϩ /CD31 Ϫ cells, the so-called saphenous vein-derived pericytes, were described to improve the degree of neovascularization and recovery of blood flow in the ischemic limbs through paracrine mechanism. 41 Therefore, it would be intriguing to see whether the combination of freshly isolated SVF and cultured pericytes could achieve a much higher neovascularization capacity than freshly isolated SVF alone in the future. Within the scope of clinical application, SAT would serve as a feasible and practical source of SVF. However, we found a limitation using SVF as allograft for therapeutic neovascularization. A possible limitation of the clinical applications using this approach is the risk of immune rejection caused by major histocompatibility complex class I mismatching between the implanted donor SVF and the recipient. Thus, the implantation of freshly isolated SVF is restricted to autograft and isograft approaches.
Taking the advantages of SVF, we next attempted to explore the potential therapeutic applications of SVF in preclinical studies. We focused on 2 aspects: protective effect against ischemia and supportive role in fat autografts. To test whether SVF implants can treat ischemia, we adopted the mouse ischemic hindlimb model, which we assume to represent human peripheral arterial occlusive disease. Compared with the control, the SVF-implanted mice showed improved perfusion, as well as an encouragingly higher rate of hindlimb preservation. This suggests that SVF does possess protective characteristics against ischemia and may be able to minimize the ischemic penumbra during the acute/subacute stage of an ischemic crisis. Autologous fat tissue augmentation is a widely adopted method for a variety of cosmetic and reconstructive surgeries. 23, 27, 42 However, the major drawback of fat autograft is the inevitable fat absorption, that occurs up to 70%, 25 in which the graft is interrupted. In such cases, the compromised circulation of the graft and a major shift in the microenvironment would jeopardize the integrity of the transplanted adipocytes. Therefore, we postulated that enriching the vascular supply with coimplantation of SVF might improve the microenvironment and survival of the graft. Our results suggest that the coimplantation of SVF might prevent or delay fat absorption in autologous fat augments and could be exploited as an adjuvant therapy of fat transplantation.
In conclusion, SVF found in adipose tissue can generate a rapid and robust construction of a vascular network through a mechanism that we attribute to the dynamic reassembly of BECs. Although the possible clinical applications and protocols for SVF-based cell therapy must be further optimized, we have demonstrated the possibility of therapeutic applications of SVF to be promising for treatment of diseases that could benefit from therapeutic neovascularization and prevention of fat absorption in autologous fat augments.
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